Drugs / ALN-6400
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06659640 | Nov 2024 → Jan 2028 expected | hereditary hemorrhagic telangiectasia | Alnylam Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07575308 | Jul 2026 → Jun 2027 expected | von Willebrand disease (hereditary or acquired) | Alnylam Pharmaceuticals | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-02-25 | Alnylam Pharmaceuticals | Results Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day alnylam.com ↗
Data will be shared from the first cohort of participants in the Phase 1 study, demonstrating favorable impact on an ex-vivo hemostasis assay. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-02-25 | Alnylam Pharmaceuticals | Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day alnylam.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-6400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07575308 ↗ |
| Route | Subcutaneous | “ALN-6400 will be administered subcutaneously (SC)” NCT06659640 ↗ |